Fra selskabsmeddelelse:
Financial Performance
- Revenue increased by DKK 186 million, 28%, from DKK 664 million in 2013 to DKK 850 million in 2014, mainly driven by higher revenue related to our daratumumab and DuoBody collaborations with Janssen, partially offset by lower Arzerra royalties.
- Operating expenses were reduced from DKK 594 million in 2013 to DKK 585 million in 2014.
- Operating income improved by DKK 196 million, from DKK 69 million in 2013 to DKK 265 million in 2014.
- 2014 year end cash position of DKK 2,661 million, compared to DKK 1,557 million as of December 31, 2013.
2015 OUTLOOK
| MDKK | 2015 Guidance | 2014 Actual Result |
| Revenue | 650 – 725 | 850 |
| Operating expenses | (600) – (650) | (585) |
| Reversal of GSK liability | 175 | – |
| Operating income | 200 – 275 | 265 |
| Cash position at end of year* | 2,300 – 2,400 | 2,661 |
| *Cash, cash equivalents, and marketable securities | ||
Læs hele årsrapporten her.
